Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.

The oncologist - 5 Aug 2022

Fakih Marwan, Tu Huakang, Hsu Hil, Aggarwal Shivani, Chan Emily, Rehn Marko, Chia Victoria, Kopetz Scott

Abstract excerpt

BACKGROUND: The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 35472176
DOI: 10.1093/oncolo/oyac077
PMCID: PMC9355827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.PMID 35472176Read ↗

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.Semantic proximity Read ↗

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.Semantic proximity Read ↗

KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Semantic proximity Read ↗

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.Semantic proximity Read ↗

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal CancerSemantic proximity Read ↗

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.Semantic proximity Read ↗

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Semantic proximity Read ↗

The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.Semantic proximity Read ↗

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.Semantic proximity Read ↗

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.Semantic proximity Read ↗

Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study: The EMOGI-CRC01 StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.